Observational studyPloS one2025
Clinical characteristics, antimicrobial resistance, and mortality of neonatal bloodstream infections in Northern Tanzania, 2022-2023.
Observational study in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Article
- Clinical and laboratory parameters associated with bloodstream infections among neonates admitted to a tertiary hospital in Tanzania: a hospital-based cross-sectional study.Frontiers in pediatrics · 2026Article
- Clinical characteristics, bacterial profiles and antimicrobial resistance of neonates with bloodstream infection caused by ESKAPEEc pathogens in Southwest China.BMC infectious diseases · 2025Article
- Ceftriaxone Resistance in the Surgical Adult Intensive Care Unit at Muhimbili National Hospital, Dar es Salaam, Tanzania.The East African health research journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Neonatal bloodstream infections (BSI) make a substantial contribution to morbidity and mortality in low- and middle-income countries (LMICs), but data on the epidemiology and antimicrobial resistance (AMR) in Tanzania are limited. We describe the prevalence, resistance patterns, and associated factors of neonatal BSI at the Kilimanjaro Christian Medical Centre (KCMC), a large referral hospital in northern Tanzania. We conducted a prospective, observational study involving infants aged 0-60 days with perinatal risk factors or clinical signs of sepsis. Aerobic blood cultures were obtained at enrollment and monitored using a continuously monitored blood culture instrument. Antimicrobial susceptibility testing was performed using standard phenotypic methods. Vital status was obtained on days 2, 7, and 28 post-enrollment. BSI was defined as the isolation of established neonatal pathogens, including yeast and coagulase-negative Staphylococcus spp. (CoNS). Early-onset BSI occurred on day of life (DOL) 0-2, while late-onset BSI occurred on DOL 3 or later. Among 236 enrolled infants, blood culture was obtained in 233. BSI occurred in 106 (45.5%) of 233 infants, 50 (47.2%) were early-onset, and 56 (52.8%) were late-onset BSI. The isolated pathogens included 58 (54.7%) Gram-positive bacteria, 40 (37.7%) Gram-negative bacteria, and 8 (7.5%) yeast. CoNS (n = 55, 51.9%) and Klebsiella pneumoniae (n = 35, 33.0%) were the most common pathogens. Notably, all K. pneumoniae isolates were extended-spectrum beta-lactamase producers, resistant to ampicillin and ceftriaxone. Among the 56 infants who died, 29 (51.8%) had BSI; 11 (19.6%) infants with EO-BSI, and 18 (32.1%) with LO-BSI. Infants requiring respiratory support at admission had a 1.89-fold increased adjusted odds of BSI (95% CI, 1.05-3.44). We found high prevalence of neonatal BSI due to bacteria with a high prevalence of AMR, and BSI was associated with high mortality. There is an urgent need for effective preventive, diagnostic, and therapeutic interventions to address BSI among hospitalized infants in northern Tanzania.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.